|
1
|
Pushparaj K, Bhotla HK, Arumugam VA,
Pappusamy M, Easwaran M and Balasubramanian B: Mucormycosis (black
fungus) ensuing COVID-19 and comorbidity meets-Magnifying global
pandemic grieve and catastrophe begins. Sci Total Environ.
805(150355)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hernandez-Ramirez G, Barber D, Tome-Amat
J, Garrido-Arandia M and Diaz-Perales A: Alternaria as an inducer
of allergic sensitization. J Fungi (Basel). 7(838)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ibrahim AS, Spellberg B, Walsh TJ and
Kontoyiannis DP: Pathogenesis of mucormycosis. Clin Infect Dis. 54
(Suppl 1):S16–S22. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Skiada A, Pavleas I and
Drogari-Apiranthitou M: Epidemiology and diagnosis of mucormycosis:
An update. J Fungi (Basel). 6(265)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Singh AK, Singh R, Joshi SR and Misra A:
Mucormycosis in COVID-19: A systematic review of cases reported
worldwide and in India. Diabetes Metab Syndr.
15(102146)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Skiada A, Lass-Floerl C, Klimko N, Ibrahim
A, Roilides E and Petrikkos G: Challenges in the diagnosis and
treatment of mucormycosis. Med Mycol. 56 (Suppl 1):S93–S101.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Borkar SG: Mucormycosis: A surge in
mucorales fungal infection in post-covid patients in Indian States
and insight into known and unknown factors. Int J Global Health.
1:26–60. 2021.
|
|
8
|
Lu XL, Najafzadeh MJ, Dolatabadi S, Ran
YP, Gerrits van den Ende AH, Shen YN, Li CY, Xi LY, Hao F, Zhang
QQ, et al: Taxonomy and epidemiology of Mucor irregularis, agent of
chronic cutaneous mucormycosis. Persoonia. 30:48–56.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Aranjani JM, Manuel A, Abdul Razack HI and
Mathew ST: COVID-19-associated mucormycosis: Evidence-based
critical review of an emerging infection burden during the
pandemic's second wave in India. PLoS Negl Trop Dis.
15(e0009921)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Alom S, Ali F and Md ZK: A comprehensive
review on mucormycosis (Black fungus) and its association with
covid-19. Curr Trends Pharm Res. 8:11–40. 2021.
|
|
11
|
Serris A, Danion F and Lanternier F:
Disease entities in mucormycosis. J Fungi (Basel).
5(23)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ghosh D, Dey S, Chakraborty H, Mukherjee
S, Halder A, Sarkar A and Sarkar J: Mucormycosis: A new threat to
Coronavirus disease 2019 with special emphasis on India. Clin
Epidemiol Glob Health. 15(101013)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dulski TM, DeLong M, Garner K, Patil N,
Cima MJ, Rothfeldt L and Kothari A: Notes from the field:
COVID-19-Associated Mucormycosis-Arkansas, July-September 2021.
MMWR Morb Mortal Wkly Rep. 70:1750–1751. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bourcier J, Heudes PM, Morio F, Gastinne
T, Chevallier P, Rialland-Battisti F and Peterlin P: Prevalence of
the reversed halo sign in neutropenic patients compared with
non-neutropenic patients: Data from a single-centre study involving
27 patients with pulmonary mucormycosis (2003-2016). Mycoses.
60:526–533. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pérez ADC and Welsh EC: Cutaneous
mucormycosis. An Bras Dermatol. 92:304–311. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Huang SF, Ying-Jung Wu A, Shin-Jung Lee S,
Huang YS, Lee CY, Yang TL, Wang HW, Chen HJ, Chen YC, Ho TS, et al:
Review of COVID-19 associated pulmonary aspergillosis and
mucormycosis. J Microbiol Immunol Infect. 56:442–454.
2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Spellberg B: Gastrointestinal
mucormycosis: An evolving disease. Gastroenterol Hepatol (N Y).
8:140–142. 2012.PubMed/NCBI
|
|
18
|
Suresh S and Radha KV: Effect of a mixed
substrate on phytase production by Rhizopus oligosporus MTCC 556
using solid state fermentation and determination of dephytinization
activities in food grains. Food Sci Biotechnology. 24:551–559.
2015.
|
|
19
|
Lin CY, Wang IT, Chang CC, Lee WC, Liu WL,
Huang YC, Chang KW, Huang HY, Hsiao HL, Kao KC, et al: Comparison
of clinical manifestation, diagnosis, and outcomes of invasive
pulmonary aspergillosis and pulmonary mucormycosis. Microorganisms.
7(531)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shirane S, Watanabe D, Sekiya N, Horiguchi
SI and Najima Y: Paraplegia via hematogenous dissemination of
Cunninghamella elegans (mucormycosis) after hematopoietic
stem cell transplantation. Int J Infect Dis. 113:210–212.
2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Rammaert B, Lanternier F, Zahar JR,
Dannaoui E, Bougnoux ME, Lecuit M and Lortholary O:
Healthcare-associated mucormycosis. Clin Infect Dis. 54 (Suppl
1):S44–S54. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
India Today: Black fungus detected in
Covid-19 survivors, 8 lose eyesight in Surat. India Today TV, New
Delhi, 2021. https://www.indiatoday.in/coronavirus-outbreak/story/black-fungus-mucormycosis-detected-covid19-survivors-8-lose-eyesight-surat-fungal-infection-symptoms-1799971-2021-05-07?utm_source=washare&utm_medium=socialicons&utm_campaign=shareurltracking.
Updated: May 20, 2021.
|
|
23
|
Reed C, Bryant R, Ibrahim AS, Edwards J
Jr, Filler SG, Goldberg R and Spellberg B: Combination
polyene-caspofungin treatment of rhino-orbital-cerebral
mucormycosis. Clin Infect Dis. 47:364–371. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Vaughan C, Bartolo A, Vallabh N and Leong
SC: A meta-analysis of survival factors in rhino-orbital-cerebral
mucormycosis-has anything changed in the past 20 years. Clin
Otolaryngol. 43:1454–1464. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yohai RA, Bullock JD, Aziz AA and Markert
RJ: Survival factors in rhino-orbital-cerebral mucormycosis. Surv
Ophthalmol. 39:3–22. 1994.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jeong W, Keighley C, Wolfe R, Lee WL,
Slavin MA, Kong DCM and Chen SA: The epidemiology and clinical
manifestations of mucormycosis: A systematic review and
meta-analysis of case reports. Clin Microbiol Infect. 25:26–34.
2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Roden MM, Zaoutis TE, Buchanan WL, Knudsen
TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH,
et al: Epidemiology and outcome of zygomycosis: A review of 929
reported cases. Clin Infect Dis. 41:634–653. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Prakash H and Chakrabarti A: Global
epidemiology of mucormycosis. J Fungi (Basel). 5(26)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tedder M, Spratt JA, Anstadt MP, Hegde SS,
Tedder SD and Lowe JE: Pulmonary mucormycosis: Results of medical
and surgical therapy. Ann Thor Surg. 57:1044–1050. 1994.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lee FY, Mossad SB and Adal KA: Pulmonary
mucormycosis: The last 30 years. Arch Internal Med. 159:1301–1309.
1999.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Feng J and Sun X: Characteristics of
pulmonary mucormycosis and predictive risk factors for the outcome.
Infection. 46:503–512. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Skiada A, Rigopoulos D, Larios G,
Petrikkos G and Katsambas A: Global epidemiology of cutaneous
zygomycosis. Clin Dermatol. 30:628–632. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chakrabarti A, Das A, Mandal J,
Shivaprakash MR, George VK, Tarai B, Rao P, Panda N, Verma SC and
Sakhuja V: The rising trend of invasive zygomycosis in patients
with uncontrolled diabetes mellitus. Med Mycol. 44:335–342.
2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Simbli M, Hakim F, Koudieh M and Tleyjeh
IM: Nosocomial post-traumatic cutaneous mucormycosis: A systematic
review. Scand J Infectious Dis. 40:577–582. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kaur H, Ghosh A, Rudramurthy SM and
Chakrabarti A: Gastrointestinal mucormycosis in apparently
immunocompetent hosts-A review. Mycoses. 61:898–908.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Dioverti MV, Cawcutt KA, Abidi M, Sohail
MR, Walker RC and Osmon DR: Gastrointestinal mucormycosis in
immunocompromised hosts. Mycoses. 58:714–718. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Guinea J, Escribano P, Vena A, Muñoz P,
Martínez-Jiménez MDC, Padilla B and Bouza E: Increasing incidence
of mucormycosis in a large Spanish hospital from 2007 to 2015:
Epidemiology and microbiological characterization of the isolates.
PLoS One. 12(e0179136)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chakrabarti A, Chatterjee SS, Das A, Panda
N, Shivaprakash MR, Kaur A, Varma SC, Singhi S, Bhansali A and
Sakhuja V: Invasive zygomycosis in India: Experience in a tertiary
care hospital. Postgraduate Med J. 85:573–581. 2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jianhong L, Xianliang H and Xuewu J:
Isolated renal mucormycosis in children. J Urol. 171:387–388.
2004.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Bhadauria D, Etta P, Chelappan A, Gurjar
M, Kaul A, Sharma RK, Gupta A, Prasad N, Marak RS, Jain M, et al:
Isolated bilateral renal mucormycosis in apparently immunocompetent
patients-a case series from India and review of the literature.
Clin Kidney J. 11:769–776. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Skiada A, Pagano L, Groll A, Zimmerli S,
Dupont B, Lagrou K, Lagrou K, Lass-Florl C, Bouza E, Klimko N, et
al: Zygomycosis in Europe: Analysis of 230 cases accrued by the
registry of the European Confederation of Medical Mycology (ECMM)
Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol
Infect. 17:1859–1867. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Anjum NA: Mucormycosis: Botanical insights
into the major causative agents, 8 June, 2021.
|
|
43
|
Prakash H, Singh S, Rudramurthy SM, Singh
P, Mehta N, Shaw D and Ghosh AK: An aero mycological analysis of
Mucormycetes in indoor and outdoor environments of northern India.
Med Mycol. 58:118–123. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Prakash H and Chakrabarti A: Epidemiology
of mucormycosis in India. Microorganisms. 9(523)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ravindra K and Ahlawat A: Five probable
factors responsible for the COVID-associated mucormycosis outbreak
in India. Int J Infectious Dis. 112:278–280. 2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Alim A, Pati BK, Sarfraz A and Bharti B:
Rhinocerebral mucormycosis in a diabetic patient: A case report
with brief review. Int J Med Res Prof. 5:150–154. 2019.
|
|
47
|
Mohindra S, Mohindra S, Gupta R, Bakshi J
and Gupta SK: Rhinocerebral mucormycosis: The disease spectrum in
27 patients. Mycoses. 50:290–296. 2007.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Almas T, Nazar W, Khedro T, Kanawati MA,
Adnan A, Almuhaileej M, Alshamlan A, Abdulhadi A, Manamperi KT and
Sarfraz S: COVID-19 and mucormycosis superinfection: Exploring the
missing pathophysiological links. Ann Med Surg (Lond).
68(102655)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Aggarwal S, Gollapudi S, Yel L, Gupta AS
and Gupta S: TNF-α-induced apoptosis in neonatal lymphocytes:
TNFRp55 expression and downstream pathways of apoptosis. Genes
Immunity. 1:271–279. 2000.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Fischer K, Hoffmann P, Voelkl S,
Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G,
Hoves S, et al: Inhibitory effect of tumor cell-derived lactic acid
on human T cells. Blood. 109:3812–3819. 2007.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Johnson AK, Ghazarian Z, Cendrowski KD and
Persichino JG: Pulmonary aspergillosis and mucormycosis in a
patient with COVID-19. Med Mycol Case Rep. 32:64–67.
2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Patel A, Kaur H, Xess I, Michael JS, Savio
J, Rudramurthy S, Singh R, Shastri P, Umabala P, Sardana R, et al:
A multicentre observational study on the epidemiology, risk
factors, management and outcomes of mucormycosis in India. Clin
Microbiol Infect. 26:944.e9–944.e15. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Khanna M, Challa S, Kabeil AS, Inyang B,
Gondal FJ, Abah GA, Minnal Dhandapani M, Manne M and Mohammed L:
Risk of mucormycosis in diabetes mellitus: A systematic review.
Cureus. 13(e18827)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Indu DP, Yadhav MLK and Chetana GS: Is
serum ferritin an early marker for COVID-19-associated
mucormycosis? Cureus. 15(e36734)2023.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Pilmis B, Alanio A, Lortholary O and
Lanternier F: Recent advances in the understanding and management
of mucormycosis. F1000Research. 7(F1000 Faculty
Rev-1429)2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Millon L, Larosa F, Lepiller Q, Legrand F,
Rocchi S, Daguindau E, Scherer E, Bellanger AP, Leroy J and
Grenouillet F: Quantitative polymerase chain reaction detection of
circulating DNA in serum for early diagnosis of mucormycosis in
immunocompromised patients. Clin Infect Dis. 56:e95–e101.
2013.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Guegan H, Iriart X, Bougnoux ME, Berry A,
Robert-Gangneux F and Gangneux JP: Evaluation of
MucorGenius® mucorales PCR assay for the diagnosis of
pulmonary mucormycosis. J Infect. 81:311–317. 2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Muley P, Chitguppi R and Jambure R:
Proposal for a novel grading system for rhino-maxillary
mucormycosis based on the analysis of 30 cases. (May 27, 2021).
Available at SSRN: https://ssrn.com/abstract=3854282 or http://dx.doi.org/10.2139/ssrn.3854282.
|
|
59
|
Tissot F, Agrawal S, Pagano L, Petrikkos
G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C and
Herbrecht R: ECIL-6 guidelines for the treatment of invasive
candidiasis, aspergillosis and mucormycosis in leukemia and
hematopoietic stem cell transplant patients. Haematologica.
102:433–444. 2017.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Meyer RD: Current role of therapy with
amphotericin B. Clinical infectious diseases. 14 (Suppl
1):S154–S160. 1992.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Dash AK, Patro S, Patro SK, Gupta AK and
Biswal RN: Amphotericin B emulsion in rhino-orbital mucormycosis:
Is it most effective? Clinical Rhinol An Inter J. 9:40–42.
2016.
|
|
62
|
Torrado JJ, Espada R, Ballesteros MP and
Torrado-Santiago S: Amphotericin B formulations and drug targeting.
J Pharm Sci. 97:2405–2425. 2008.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Liu T, Wang L and Liu CT: Cavitary
pulmonary mucormycosis caused by Cunninghamella in a patient with
diabetes. Am J Med Sci. 364:245–247. 2022.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Fernández-García R, Muñoz-García JC,
Wallace M, Fabian L, González-Burgos E, Gómez-Serranillos MP,
Raposo R, Bolás-Fernández F, Ballesteros MP, Healy AM, et al:
Self-assembling, supramolecular chemistry and pharmacology of
amphotericin B: Poly-aggregates, oligomers and monomers. J Control
Release. 341:716–732. 2022.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Kim MJ, Park PW, Ahn JY, Kim KH, Seo JY,
Jeong JH, Park MJ, Jung JW and Seo YH: Fatal pulmonary mucormycosis
caused by Rhizopus microsporus in a patient with diabetes. Ann Lab
Med. 34:76–79. 2014.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Odds FC, Brown AJ and Gow NA: Antifungal
agents: Mechanisms of action. Trends Microbiol. 11:272–279.
2003.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Pettit NN and Carver PL: Isavuconazole: A
new option for the management of invasive fungal infections. Ann
Pharmacother. 49:825–842. 2015.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Marty FM, Ostrosky-Zeichner L, Cornely OA,
Mullane KM, Perfect JR, Thompson GR III, Alangaden GJ, Brown JM,
Fredricks DN, Heinz WJ, et al: Isavuconazole treatment for
mucormycosis: A single-arm open-label trial and case-control
analysis. Lancet Infect Dis. 16:828–837. 2016.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Mohsina FP, Faheem IP, Tabassum S, Shah I
and Ahmad A: An insight of mucormycosis (black fungus) in ayurveda.
Open J Pharmacol Pharmacother. 6:13–17. 2021.
|
|
70
|
Adluri USP and Perugu S: Evaluation of
efficacy and safety of adjuvant Ayurvedic therapy in patients with
severe post-covid mucor-mycosis at a Government tertiary care
hospital-A Case-Control study. J Ayurveda Integr Med.
13(100585)2022.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Jangid R and Begum T: Antimycotic activity
of some medicinal plants against Mucor circinelloides. Biomed Res
Int. 2022(3523920)2022.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Balkrishna A, Rastogi S, Kharayat B, Tomer
M, Varshney Y, Singh K, Kumari P, Dev R, Srivastava J, Haldar S and
Varshney A: Anu taila, an herbal nasal drop, suppresses
mucormycosis by regulating host TNF-α response and fungal
ergosterol biosynthesis. J Appl Microbiol. 132:3355–3374.
2022.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Sharma S, Grover M, Bhargava S, Samdani S
and Kataria T: Post coronavirus disease mucormycosis: A deadly
addition to the pandemic spectrum. J Laryngol Otol. 135:442–447.
2021.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Szebenyi C, Gu Y, Gebremariam T, Kocsubé
S, Kiss-Vetráb S, Jáger O, Patai R, Spisák K, Sinka R, Binder U, et
al: CotH genes are necessary for normal spore formation and
virulence in Mucor lusitanicus. mBio. 14(e0338622)2023.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Chaudhary P and Singh P: Isolation,
identification and molecular characterization of microflora
obtained from spices and spice mixes. World J Pharmaceutical Res.
3:2020–2030. 2014.
|
